Article
Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2015
Shan Ling, Wang Ziping, Guo Lei, Sun Hongyan, Qiu Tian, Ling Yun, Li Wenbin, Li Lin, Liu Xiuyun, Zheng Bo, Lu Ning, Ying Jianming
Abstract excerpt
OBJECTIVES: Tumor heterogeneity, which causes different EGFR mutation abundance, is believed to be responsible for varied progression-free survival (PFS) in lung adenocarcinoma (ADC) patients receiving EGFR-TKI treatment. Frequent EGFR amplification and its common affection in EGFR mutant allele promote the hypothesis that EGFR mutant abundance might be determined by EGFR copy number variation and therefore...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.